In Vitro Generation of Myeloid Derived Suppressor Cells

The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF).

Anti-lilrb2 antibodies and methods of use thereof

Antibodies and antibody fragments that specifically bind to LILRB2 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB2 and methods of use thereof. Also provided are related chimeric antigen receptors (CARs) and cells comprising same (e.g., T cells, natural killer cells, or macrophages), and uses of the CARs and cells in targeting tumors and killing them, asthma treatment, or in targeting and removing infected cells (e.g., to treat infections or infectious diseases), or in suppressing immune system cells, as involved in autoimmune disease or transplant rejection.

ANTI-LILRB3 ANTIBODIES AND METHODS OF USE THEREOF

Antibodies and antibody fragments that specifically bind to LILRB3 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB3 and methods of use thereof. 1. (canceled)2. (canceled)3. An antibody or antigen-binding fragment thereof that specifically binds to leukocyte immunoglobulin-like receptor B3 (LILRB3) , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) , wherein:(i) the VH comprises VH complementarity determining region (CDR)1, CDR2, and CDR3 comprising the amino acid sequences GYTFTTYG (SEQ ID NO: 44), MNTYSGVP (SEQ ID NO: 59), and CARMGRGSLYGMDYW (SEQ ID NO: 71), respectively, and the VL comprises VL CDR1, CDR2, and CDR3 comprising the amino acid sequences QSLLISTNQKNY (SEQ ID NO: 1), FAS (SEQ ID NO: 18) and CQQHYSIPPTF (SEQ ID NO: 27), respectively;(ii) the VH comprises VH CDR1, CDR2, and CDR3 comprising the amino acid sequences GYTFTTYG (SEQ ID NO: 44), INTYSGVP (SEQ ID NO: 60) and CARSGHSYSLYVMGYW (SEQ ID NO: 72), respectively, and the VL comprises VL CDR1, CDR2, and CDR3 comprising the amino acid sequences QSLFISTNQKNY (SEQ ID NO: 2), FAS (SEQ ID NO: 18) and CQQHYSSPPTF (SEQ ID NO: 28), respectively;(iii) the VH comprises VH CDR1, CDR2, and CDR3 comprising the amino acid sequences GYTFTTYG (SEQ ID NO: 44), INTYSGVP (SEQ ID NO: 60) and CARSGHNYSLYVMGYW (SEQ ID NO: 73), respectively, and the VL comprises VL CDR1, CDR2, and CDR3 comprising the amino acid sequences QSLFISTNQKNY (SEQ ID NO: 2), FAS (SEQ ID NO: 18) and CQQHYSSPPTF (SEQ ID NO: 28), respectively;(iv) the VH comprises VH CDR1, CDR2, and CDR3 comprising the amino acid sequences GYTFTTYG (SEQ ID NO: 44), INTYSGVP (SEQ ID NO: 60) and CARGALYYFDNW (SEQ ID NO: 74), respectively, and the VL comprises VL CDR1, CDR2, and CDR3 comprising the amino acid sequences QSLLISTNQINY (SEQ ID NO: 3), FAS (SEQ ID NO: 18) and CQQHYDPPLTF (SEQ ID NO: 29), ...

In vitro generation of myeloid derived suppressor cells

The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MDSCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF).

Anti-lilrb3 antibodies and methods of use thereof

Anti-LILRB3 antibodies and methods of use thereof

Antibodies and antibody fragments that specifically bind to LILRB3 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB3 and methods of use thereof.

Compositions and therapeutic agents for modulating inflammatory responses on both tumor and immune cells

Disclosed are compositions and methods related to the detection, prognosis and treatment of a cancer related to the expression level of CMTM4. In one aspect, the disclosure provides for siRNAs and small molecules that can inhibit CMTM4 for the treatment of cancer.

Anti-lilrb3 antibodies and methods of use thereof

Antibodies and antibody fragments that specifically bind to LILRB3 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB3 and methods of use thereof.

Compositions and therapeutic agents for modulating inflammatory responses on both tumor and immune cells

The relationship between macrophage polarization and cancer progression depending on tumor location and microenvironment has been elusive. New agents and methods for directing macrophage polarization and modulating the host immune response are needed. Disclose are compositions and methods related to the detection, prognosis and treatment of a cancer related to the expression level of CMTM4. In one aspect, the disclosure provides for siRNAs and small molecules that can inhibit CMTM4 for the treatment of cancer.

Lilrb2 binding molecules and methods of use

Disclosed are anti-LILRB2 binding molecules and methods of their use in the treatment of cancer and microbial infection.

Lilrb2 binding molecules and methods of use

Disclosed are anti-LILRB2 binding molecules and methods of their use in the treatment of cancer and microbial infection.